nach oben

Virchows Archiv

Erschienen in:

01.07.2012 | Original Article

Co-expression of VEGF and CA9 in ovarian high-grade serous carcinoma and relationship to survival

verfasst von: Emma Williams, Stewart Martin, Robert Moss, Lindy Durrant, Suha Deen

Erschienen in: Virchows Archiv | Ausgabe 1/2012

Einloggen, um Zugang zu erhalten

Abstract

Poor prognosis in ovarian high-grade serous carcinoma (HGSC) is largely related to resistance to chemotherapy. Tumour hypoxia is known to be associated with chemotherapy resistance. Stabilisation of hypoxia-inducible factor-1α upregulates the expression of downstream genes such as carbonic anhydrase 9 (CA9) and vascular endothelial growth factor (VEGF). This study was undertaken to analyse the hypoxia profile as indicated by the co-expression of VEGF and CA9 and its correlation with survival. VEGF and CA9 expressions were examined in tissue microarray of 97 cases of ovarian high-grade serous carcinoma using immunohistochemistry. High expression of either VEGF or CA9, individually, was associated with decreased overall survival (p = 0.006 and p = 0.05 respectively). Combined high expression of both markers, to give a ‘hypoxia profile’, was associated with chemotherapy resistance (p = 0.036) and showed worse overall survival with a significant p value (p = 0.001). Using multivariate analysis, hypoxia profile was an independent prognostic factor for overall survival (p = 0.028). The combined high expression CA9 and VEGF phenotype, described as high hypoxia profile group, was significantly associated with increased resistance to chemotherapy and poor overall survival. This group may benefit from combined targeted therapy for effective response in ovarian HGSC.

Westfall D, Roma AA, Silva EG (2009) High-grade serous carcinoma of the ovary. Ann Diagn Pathol 13(4):285–290PubMedCrossRef

Burger RA (2011) Overview of anti-angiogenic agents in development for ovarian cancer. Gynecol Oncol 121:230–238PubMedCrossRef

Semenza GL (2001) Regulation of hypoxia-induced angiogenesis: a chaperone escorts VEGF to the dance. J Clin Invest 108:39–40PubMed

Ziello JE, Jovin IS, Huang Y (2007) Hypoxia-inducible factor (HIF)-1 regulatory pathway and its potential for therapeutic intervention in malignancy and ischemia. Yale J Biol Med 80(2):51–60PubMed

Ruan K, Song G, Ouyang G (2009) Role of hypoxia in the hallmarks of human cancer. J Cell Biochem 107:1053–1062PubMedCrossRef

Wykoff CC, Beasley NJ, Watson PH et al (2000) Hypoxia-inducible expression of tumour-associated carbonic anhydrases. Cancer Res 60:7075–7083PubMed

Shannon AM, Bouchier-Hayes DJ, Condron CM et al (2003) Tumour hypoxia, chemotherapeutic resistance and hypoxia-related therapies. Cancer Treat Rev 29(4):297–307PubMedCrossRef

Potter CPS, Harris AL (2003) Diagnostic, prognostic and therapeutic implications of carbonic anhydrases in cancer. Br J Cancer 89:2–7PubMedCrossRef

Hockel M, Schlenger K, Aral B et al (1996) Association between tumor hypoxia and malignant progression in advanced cancer of the uterine cervix. Cancer Res 56:4509–4515PubMed

10.

Brizel DM, Scully SP, Harrelson JM et al (1996) Tumor oxygenation predicts for the likelihood of distant metastases in human soft tissue sarcoma. Cancer Res 56:941–943PubMed

11.

Mahoney BP, Raghunand N, Baggett B et al (2003) Tumor acidity, ion trapping and chemotherapeutics I. Acid pH affects the distribution of chemotherapeutic agents in vitro. Biochem Pharmacol 66:1207–1218PubMedCrossRef

12.

Hussain SA, Ganesan R, Reynolds G et al (2007) Hypoxia-regulated carbonic anhydrase IX expression is associated with poor survival in patients with invasive breast cancer. Br J Cancer 96(1):104–109PubMedCrossRef

13.

Loncaster JA, Harris AL, Davidson SE et al (2001) Carbonic anhydrase (CA IX) expression, a potential new intrinsic marker of hypoxia: correlations with tumour oxygen measurements and prognosis in locally advanced carcinoma of the cervix. Cancer Res 61(17):6394–6399PubMed

14.

Kim SJ, Rabbani ZN, Dewhirst MW et al (2005) Expression of HIF-1α, CA IX, VEGF and MMP-9 in surgically resected non-small cell lung cancer. Lung Cancer 49(3):325–335PubMedCrossRef

15.

Driessen A, Landuyt W, Pastorekova S et al (2006) Expression of carbonic anhydrase IX (CA IX), a hypoxia-related protein, rather than vascular-endothelial growth factor (VEGF), a pro-angiogenic factor, correlates with an extremely poor prognosis in esophageal and gastric adenocarcinomas. Ann Surg 243:334–340PubMedCrossRef

16.

Hui EP, Chan ATC, Pezzella F et al (2002) Coexpression of hypoxia-inducible factors 1α and 2α, carbonic anhydrase IX, and vascular endothelial growth factor in nasopharyngeal carcinoma and relationship to survival. Clin Cancer Res 8:2595–2604PubMed

17.

Hynninen P, Vaskivuo L, Saarnio J et al (2006) Expression of transmembrane carbonic anhydrases IX and XII in ovarian tumours. Histopathology 49:594–602PubMedCrossRef

18.

Eisenhauer EA, Therasse P, Bagaerts J et al (2009) New response evaluation criteria in solid tumors: revised RECIT guideline (Version 1.1). Eur J Cancer 45:228–247PubMedCrossRef

19.

Markman M, Hoskins W (1992) Responses to salvage chemotherapy in ovarian cancer: a critical need for precise definitions of the treated population. J Clin Oncol 10(4):513–514PubMed

20.

Rosen DG, Huang X, Deavers MT et al (2004) Validation of tissue microarray technology in ovarian carcinoma. Mod Pathol 17:790–797PubMedCrossRef

21.

Camp RL, Charette LA, Rimm DL (2000) Validation of tissue microarray technology in breast carcinoma. Lab Invest 80(12):1943–1949PubMedCrossRef

22.

Kononen J, Bubendorf L, Kallioniemi A et al (1998) Tissue microarrays for high-throughput molecular profiling of tumour specimens. Nat Med 4:844–847PubMedCrossRef

23.

Shibata D, Martin WJ, Arnheim N (1988) Analysis of DNA sequences in forty-year-old paraffin-embedded thin-tissue sections: a bridge between molecular biology and classical histology. Cancer Res 48:4564–4566PubMed

24.

McCarty KS Jr, Miller LS, Cox EB et al (1985) Estrogen receptor analyses. Correlation of biochemical and immuno-histochemical methods using monoclonal antireceptor antibodies. Arch Pathol Lab Med 109:716–721PubMed

25.

Camp RL, Dolled-Filhart M, Rimm DL (2004) X-tile: a new bio-informatics tool for biomarker assessment and outcome-based cut-point optimization. Clin Cancer Res 10:7252–7259PubMedCrossRef

26.

Phuoc NB, Ehara H, Gotoh T et al (2008) Prognostic value of the co-expression of carbonic anhydrase IX and vascular endothelial growth factor in patients with clear cell renal cell carcinoma. Oncol Rep 20:525–530PubMed

27.

Duncan TJ, Al-Attar A, Rolland P et al (2008) Vascular endothelial growth factor expression in ovarian cancer: a model for targeted use of novel therapies? Clin Cancer Res 14(10):3030–3035PubMedCrossRef

28.

Greenberg S, Rugo HS (2010) Triple-negative breast cancer: role of antiangiogenic agents. Cancer J 16(1):33–38PubMedCrossRef

29.

Sivridis E, Giatromanolaki A, Gatter KC et al (2002) Association of hypoxia-inducible factors 1α and 2α with activated angiogenic pathways and prognosis in patients with endometrial carcinoma. Cancer 95(5):1055–63PubMedCrossRef

30.

Saarnio J, Parkkila S, Parkkila A et al (1998) Immunohistochemical study of colorectal tumour for expression of a novel transmembrane carbonic anhydrase MN/CA IX, with potential value as a marker of cell proliferation. Am J Pathol 153(1):279–285PubMedCrossRef

31.

Birner P, Schindl M, Obermair A et al (2001) Expression of hypoxia-inducible factor 1a in epithelial ovarian tumors: its impact on prognosis and on response to chemotherapy. Clin Cancer Res 7:1661–1668PubMed

32.

Wouters BG, Weppler SA, Koritzinsky M et al (2002) Hypoxia as a target for combined modality treatments. Eur J Cancer 38:240–257PubMedCrossRef

33.

Jubb AM, Pham TQ, Hanby AM et al (2004) Expression of vascular endothelial growth factor, hypoxia inducible factor 1alpha, and carbonic anhydrase IX in human tumours. J Clin Pathol 57:504–512PubMedCrossRef

Titel: Co-expression of VEGF and CA9 in ovarian high-grade serous carcinoma and relationship to survival
verfasst von: Emma Williams
Stewart Martin
Robert Moss
Lindy Durrant
Suha Deen
Publikationsdatum: 01.07.2012
Verlag: Springer-Verlag
Erschienen in: Virchows Archiv / Ausgabe 1/2012
Print ISSN: 0945-6317
Elektronische ISSN: 1432-2307
DOI: https://doi.org/10.1007/s00428-012-1252-9

Neu im Fachgebiet Pathologie

01.04.2024 | Forensische Traumatologie | CME

Springer Medizin

Co-expression of VEGF and CA9 in ovarian high-grade serous carcinoma and relationship to survival

Abstract

Neu im Fachgebiet Pathologie

Theoretische Grundlagen von Explosionen und Explosionsverletzungen

Auswirkungen vorgeschalteter Laborprozesse auf die Digitalisierung histologischer Schnittpräparate

Knochenmarkhistologie bei Zytopenien

Herausforderungen der Automation bei der quantitativen Auswertung von Leberbiopsien

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 1/2012

Urothelial carcinoma with abundant myxoid stroma: evidence for mucus production by cancer cells

Interpretation of needle biopsies of the kidney for investigation of renal masses

Histological examination and evaluation of donor bile ducts received during orthotopic liver transplantation—a morphological clue to ischemic-type biliary lesion?

Board examination for anatomical pathology in Switzerland: two intense days to verify professional competence

FGFR1 expression and gene copy numbers in human lung cancer

Polymorphic lymphoid proliferations occurring in HIV-positive patients: report of a case responding to HAART

Neu im Fachgebiet Pathologie

Theoretische Grundlagen von Explosionen und Explosionsverletzungen

Auswirkungen vorgeschalteter Laborprozesse auf die Digitalisierung histologischer Schnittpräparate

Knochenmarkhistologie bei Zytopenien

Herausforderungen der Automation bei der quantitativen Auswertung von Leberbiopsien